Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 2
2016 4
2017 4
2018 9
2019 11
2020 8
2021 10
2022 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Results by year

Filters applied: . Clear all
Page 1
Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer.
Ramirez PT, Frumovitz M, Pareja R, Lopez A, Vieira M, Ribeiro R, Buda A, Yan X, Shuzhong Y, Chetty N, Isla D, Tamura M, Zhu T, Robledo KP, Gebski V, Asher R, Behan V, Nicklin JL, Coleman RL, Obermair A. Ramirez PT, et al. Among authors: asher r. N Engl J Med. 2018 Nov 15;379(20):1895-1904. doi: 10.1056/NEJMoa1806395. Epub 2018 Oct 31. N Engl J Med. 2018. PMID: 30380365 Clinical Trial.
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.
Poveda A, Floquet A, Ledermann JA, Asher R, Penson RT, Oza AM, Korach J, Huzarski T, Pignata S, Friedlander M, Baldoni A, Park-Simon TW, Tamura K, Sonke GS, Lisyanskaya A, Kim JH, Filho EA, Milenkova T, Lowe ES, Rowe P, Vergote I, Pujade-Lauraine E; SOLO2/ENGOT-Ov21 investigators. Poveda A, et al. Among authors: asher r. Lancet Oncol. 2021 May;22(5):620-631. doi: 10.1016/S1470-2045(21)00073-5. Epub 2021 Mar 18. Lancet Oncol. 2021. PMID: 33743851 Clinical Trial.
Incidence of adverse events in minimally invasive vs open radical hysterectomy in early cervical cancer: results of a randomized controlled trial.
Obermair A, Asher R, Pareja R, Frumovitz M, Lopez A, Moretti-Marques R, Rendon G, Ribeiro R, Tsunoda A, Behan V, Buda A, Bernadini MQ, Zhao H, Vieira M, Walker J, Spirtos NM, Yao S, Chetty N, Zhu T, Isla D, Tamura M, Nicklin J, Robledo KP, Gebski V, Coleman RL, Salvo G, Ramirez PT. Obermair A, et al. Among authors: asher r. Am J Obstet Gynecol. 2020 Mar;222(3):249.e1-249.e10. doi: 10.1016/j.ajog.2019.09.036. Epub 2019 Oct 3. Am J Obstet Gynecol. 2020. PMID: 31586602 Free PMC article. Clinical Trial.
Recurrent time-to-event models with ordinal outcomes.
Gebski V, Byth K, Asher R, Marschner I. Gebski V, et al. Among authors: asher r. Pharm Stat. 2021 Jan;20(1):77-92. doi: 10.1002/pst.2057. Epub 2020 Oct 2. Pharm Stat. 2021. PMID: 33006268
High-dose chemotherapy for relapsed germ cell tumours: outcomes in low-volume specialized centres.
Connolly EA, Weickhardt A, Grimison P, Asher R, Heller GZ, Lewin J, Liow E, Toner G, Tung ILY, Tran B, Hill S, Walpole E, McKenzie J, Kuchel A, Goh J, Forgeson G, Tan A, Joshi A, Wickham A, Tan H, Wang Y, Winstanley MA, Hamad N, Wong V. Connolly EA, et al. Among authors: asher r. BJU Int. 2022 Jun;130 Suppl 1:5-16. doi: 10.1111/bju.15648. Epub 2022 Mar 31. BJU Int. 2022. PMID: 35355402 Review.
Predictive value of chromosome 18q11.2-q12.1 loss for benefit from bevacizumab in metastatic colorectal cancer: A post hoc analysis of the randomized phase III-trial AGITG-MAX.
van Dijk E, van Werkhoven E, Asher R, Mooi JK, Espinoza D, van Essen HF, van Tinteren H, van Grieken NCT, Punt CJA, Tebbutt NC, Ylstra B. van Dijk E, et al. Among authors: asher r. Int J Cancer. 2022 Oct 1;151(7):1166-1174. doi: 10.1002/ijc.34061. Epub 2022 May 23. Int J Cancer. 2022. PMID: 35489024 Free PMC article. Clinical Trial.
Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study.
Trillsch F, Mahner S, Ataseven B, Asher R, Aryal N, Dubot C, Clamp A, Penson RT, Oza A, Amit A, Huzarski T, Casado A, Scambia G, Friedlander M, Colombo N, Fujiwara K, Sonke GS, Denys H, Lowe ES, Lee CK, Pujade-Lauraine E. Trillsch F, et al. Among authors: asher r. Gynecol Oncol. 2022 Apr;165(1):40-48. doi: 10.1016/j.ygyno.2022.01.024. Epub 2022 Jan 31. Gynecol Oncol. 2022. PMID: 35115180 Clinical Trial.
47 results